논문검색
Author Yong Tai Kim, M.D.1,2,3,4, Joo Hyuk Sohn, M.D.1,2,3,4, So Hun Kim, M.D.3, Sun Young Rha, M.D., Ph D.1,2,3,4, Chul Kim, M.D.3, Jae Kyung Roh, M.D., Ph D.1,2,3,4, Byung Soo Kim, M.D., Ph D.1,2, Woo Ick Jang, M.D., Ph.D.5 and Hyun Cheol Chung, M.D., Ph D.1,2,3,4
Place of duty 1Cancer Metastasis Reserch Center, 2Yonsei Cancer Center, 3Division of Hemato-Oncology, Department of Internal Medicine, 4Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 5Lilly Korea, Ltd., Seoul, Korea
Title Infusional 5-Fluorouracil, Leucovorin and Docetaxel in Advanced Gastric Cancer
Publicationinfo Cancer Research and Treatment 2003 Apr; 035(02): 123-129.
Key_word Stomach neoplasm, Combination Chemotherapy, Infusional 5-FU, Leucovorin, Docetaxel
Full-Text
Abstract Purpose: This study was performed to estimate the response rate and toxicity of a combination chemotherapy, which included infusional 5-Fluorouracil, Leucovorin and Docetaxel in the treatment of patients with an advanced gastric carcinoma.

Materials and Methods: Twenty two advanced gastric cancer patients, with a bidimensionally measurable or an evaluable disease, were enrolled in this study. The patients received a 5-fluorouracil 1,000 mg/m2 intravenous (IV) 24 hour infusion (Day 1∼3), leucovorin 20 mg/m2 (Day 1∼3) and docetaxel 75 mg/m2 intravenously (Day 2) every 3 weeks.

Results: The overall response rate was 45.0%. The median duration of response was 10.0 weeks (range: 4∼24), the median time to response was 8 weeks (range: 8∼20) the median time to progression was 30.0 weeks (95% CI: 16.3∼43.2) and the median overall survival duration was 36.0 weeks (95% CI: 1.7∼70.2). The median cumulative dose of 5-fluorouracil were 316.2 mg/m2/week and docetaxel was 23.9 mg/m2/week. WHO grade III, IV neutropenia, thromocytopenia and anemia occurred in 50.0%, 4.5% and 4.5% of patients, respectively. There were no occurrence of WHO grade III and IV nausea, vomiting, mucositis, conspitation, diarrhea, or neurotoxicity.

Conclusion: This chemotherapy regimen, including infusional 5-fluorouracil, leucovorin and docetaxel was an active agent against advanced gastric cancer patients, especially for previous chemotherapy naive patients. (Cancer Research and Treatment 2003;35:123⁣129)